Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Artiva Biotherapeutics (NASDAQ: ARTV)*

Finance & Acquisition: Artiva

Parents

2020: Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies
2020: The financing was co-led by 5AM Ventures, venBio Partners, and RA Capital Management, and joined by Medivate Partners and seed investors and strategic partners GC LabCell (Green Cross LabCell Corporation) (KRX: 144510) and GC (Green Cross Holdings Corporation) (KRX: 005250).
2021: Artiva Biotherapeutics Aims For $100 Million U.S. IPO
2021: NK cell therapy player Artiva makes some more noise, pulling in $120M Series B less than a month after Merck deal
2021: Series B round led by Venrock Healthcare Capital Partners, Acuta Capital Partners, Cormorant Asset Management, EcoR1 Capital, Franklin Templeton, Janus Henderson Investors, Logos Capital, RTW Investments, LP, Surveyor Capital (a Citadel Company), Wellington Management Company, an undisclosed leading global investment firm, 5AM Ventures, RA Capital Management, venBio Partners, and strategic partners GC LabCell and GC.